Abstract Treatment options for patients with metastatic melanoma, and especially BRAF-
mutant melanoma, have changed dramatically in the past 5 years, with the FDA approval of …

Cancer immunotherapy has revolutionized the treatment landscape in medical oncology, but
its efficacy has been variable across patients. Biomarkers to predict such differential …

Transcriptomic signatures designed to predict melanoma patient responses to PD-1
blockade have been reported but rarely validated. We now show that intra-patient …

Neoadjuvant checkpoint inhibition, in which the therapy is administered before surgery, is a
promising new approach to managing bulky but resectable melanoma, and is also being …

Background Patients with metastatic melanoma have variable responses to combination
ipilimumab and nivolumab. The objectives of this study were to examine the patterns of …

Background Metastasized or unresectable melanoma has been the first malignant tumor to
be successfully treated with checkpoint inhibitors. Nevertheless, about 40–50% of the …

Metastasis formation is the leading cause of death in cancer patients. Thus, understanding
and targeting this process is an unmet need. Crucial steps during the establishment of …

Currently, a marked number of clinical trials on cancer treatment have revealed the success
of immunomodulatory therapies based on immune checkpoint inhibitors that activate tumor …

Anti–PD-1 inhibitors have significant activity in metastatic melanoma. Responses often occur
early and may be sustained. The optimal duration of treatment with these agents is …

Advances in immunotherapy have achieved remarkable clinical outcomes in tumors with low
curability, but their effects are limited, and increasing evidence has implicated tumoral and …